Subcutaneous · GLP-1 agonist
Beinaglutide
7 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
7
Active
2
Recruiting
1
Completed
2
Sites
26
Countries
1
Endpoints
97
Composite endpoints
1
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
1
Phase 3
1
Phase 4
2
Not applicable
3
Trials by status
Not yet recruiting
1
Recruiting
1
Completed
2
Unknown
3
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Glycemic / diabetes
32
Weight & body composition
20
Cardiometabolic biomarkers
20
Other clinical outcomes
10
Safety / tolerability / PK
9
Other (unclassified)
5
MASH / liver
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
Fasting glucose, changeGlycemic
5
BMI, changeWeight
5
Body weight, absolute change (kg)Weight
5
HbA1c, changeGlycemic
4
Waist circumference, changeWeight
3
HOMA-IR (insulin sensitivity)Glycemic
3
HbA1c <7.0% achievementGlycemic
3
≥5% weight-loss respondersWeight
2
Total cholesterol, changeBiomarker
2
Triglycerides, changeBiomarker
2
LDL-C, changeBiomarker
2
HDL-C, changeBiomarker
2
Treatment-emergent AEs (any)Safety/PK
2
Postprandial glucoseGlycemic
2
AUC₀–∞Safety/PK
2
HbA1c, % changeGlycemic
1
hs-CRP, changeBiomarker
1
Serious AEs (any)Safety/PK
1
Systolic BP, changeBiomarker
1
Diastolic BP, changeBiomarker
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
7 of 7